If you require this document in another format such as Braille, large print, audio or another language please contact the Trusts Communications Team
|
|
- Gregory Phelps
- 5 years ago
- Views:
Transcription
1 MANAGEMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN ADULTS Summary statement: How does the document support patient care? Staff/stakeholders involved in development: Job titles only Division: Department: Responsible Person: Author: For use by: Purpose: This document supports: Standards and legislation This guideline supports staff in prescribing treatment for patients with a diagnosis of COPD. Lead Pharmacist Medicine Respiratory Consultants Specialist Nurses - Respiratory Medicine Respiratory Lead Consultant - COPD Lead Pharmacist Medicine (SRH) All clinical staff at Western Sussex Hospitals NHS Foundation Trust managing patients with COPD. This document outlines the Trust s treatment guidelines for Chronic Obstructive Pulmonary Disease in adults. Global Initiative for Chronic Obstructive Lung Disease s (GOLD) Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease 2017 Report Key related documents: Approved by: Divisional Governance/Management Group Medicines Optimisation Committee (MOC) Approval date: January 2018 Ratified by Board of Directors/ Committee of the Board of Directors Ratification Date: For completion by the Compliance Team. For completion by the Compliance Team. Expiry Date: January 2021 Review date: January 2021 If you require this document in another format such as Braille, large print, audio or another language please contact the Trusts Communications Team Reference Number: To be added by the Library
2 Version date Author Status Comment 1.0 May 2017 Lead Pharmacist Medicine (SRH) Superceded 2.0 January Lead Pharmacist Medicine (SRH) Addition of Trelegy Ellipta device Page 2 of 10
3 MANAGEMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN ADULTS INTRODUCTION Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and treatable disease that is characterized by persistent respiratory symptoms and airflow limitation that is due to airway and/or alveolar abnormalities usually caused by significant exposure to noxious particles or gases. The chronic airflow limitation that is characteristic of COPD is caused by a mixture of small airways disease (e.g., obstructive bronchiolitis) and parenchymal destruction (emphysema), the relative contributions of which vary from person to person. The most common respiratory symptoms include dyspnoea, cough and/or sputum production. These symptoms may be under-reported by patients. The main risk factor for COPD is tobacco smoking but other environmental exposures such as biomass fuel exposure and air pollution may contribute. Besides exposures, host factors predispose individuals to develop COPD. These include genetic abnormalities, abnormal lung development and accelerated aging. COPD may be punctuated by periods of acute worsening of respiratory symptoms (exacerbations). In most patients, COPD is associated with significant concomitant chronic diseases, which increase its morbidity and mortality. These local guidelines are based on the Global Initiative for Chronic Obstructive Lung Disease s (GOLD) Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease 2017 Report and incorporate the Coastal West Sussex Formulary and local supporting services. DIAGNOSIS & ASSESSMENT COPD should be considered in any patient who has dyspnoea, chronic cough or sputum production, and/or a history of exposure to risk factors for the disease. Spirometry is required to make the diagnosis; the presence of a post-bronchodilator FEV1/FVC < 0.70 confirms the presence of persistent airflow limitation. The goals of COPD assessment are to determine the severity of the disease, including the severity of airflow limitation, the impact of disease on the patient s health status, and the risk of future events (such as exacerbations, hospital admissions, or death), in order to guide therapy. Page 3 of 10
4 Classification of severity of airflow obstruction The GOLD classification of airflow limitation severity in COPD is shown below. Spirometry should be performed after the administration of an adequate dose of at least one short-acting inhaled bronchodilator in order to minimize variability. In patients with FEV 1 /FVC < 0.70: GOLD 1: Mild FEV1 > 80% predicted GOLD 2: Moderate 50% < FEV1 < 80% predicted GOLD 3: Severe 30% < FEV1 < 50% predicted GOLD 4: Very Severe FEV1 < 30% predicted Assessment of symptoms In the past, COPD was viewed as a disease largely characterized by breathlessness and the Modified British Medical Research Council (mmrc) Questionnaire was developed as a measure of dyspnoea. The mmrc relates well to other measures of health status and predicts future mortality risk. Score mmrc Grade 0 mmrc Grade 1 mmrc Grade 2 mmrc Grade 3 mmrc Grade 4 Description of breathlessness I only get breathless with strenuous exercise. I get short of breath when hurrying on the level or walking up a slight hill. I walk slower than people of the same age on the level because of breathlessness, or I have to stop for breath when walking on my own pace on the level. I stop for breath after walking about 100 meters or after a few minutes on the level. I am too breathless to leave the house or I am breathless when dressing or undressing. However, it is now recognized that COPD impacts patients beyond just dyspnoea. For this reason, a comprehensive assessment of symptoms is recommended using measures such as the COPD Assessment Test (CAT) (see appendix 1). The revised combined COPD assessment The GOLD refined ABCD assessment tool combines the severity of airflow limitation, an assessment of dyspnoea using mmrc or symptoms using CAT and also their history of exacerbations (including prior hospitalisations). This will lead to a group outcome of either A,B,C or D which can be used for selecting the most appropriate pharmacological management. Page 4 of 10
5 PHARMACEUTICAL MANAGEMENT Pharmacologic therapy for COPD is used to reduce symptoms, reduce the frequency and severity of exacerbations and improve exercise tolerance and health status. Inhaled Therapy Treatment of COPD should follow the GOLD 2017 treatment algorithm which utilises the GOLD groups previously mentioned: Group C Group D 2 or 1 leading to hospital admission Further exacerbation(s) LAMA + LABA LABA + ICS Further exacerbation(s) LAMA + LABA + ICS Persistent symptoms/ further exacerbation(s) LAMA LAMA LAMA + LABA LABA + ICS Exacerbation history Group A Group B Continue, stop or try alternative class of bronchodilator LAMA + LABA 0 or 1 (not leading to hospital admission) Evaluate effect A bronchodilator Persistent symptoms A long-acting bronchodilator (LABA or LAMA) mmrc 0-1 CAT < 10 Symptoms mmrc 2 CAT 10 : Preferred treatment Combining bronchodilators with different mechanisms and durations of action may increase the degree of bronchodilation with a lower risk of side-effects compared to increasing the dose of a single bronchodilator. Choice of drug depends on device suitability and dosing regimen. Inhaler technique and compliance should be checked prior to changes in medication. Short-acting bronchodilators (SABA or SAMA) Salbutamol MDI 100mcg - 2 puffs PRN Ipratropium MDI 20mcg - 2 puffs PRN Page 5 of 10
6 Long-acting beta 2 -agonists (LABA) Formoterol Easyhaler 12 mcg - 1 puff BD Serevent MDI (salmeterol) 25mcg - 2 puffs BD Long-acting muscarinic antagonists (LAMAs) Incruse Ellipta (Umeclidinium) 55mcg - 1 puff OD Spiriva Handihaler (Tiotropium) 18mcg - 1 puff OD Spiriva Respimat (Tiotropium) 2.5mcg - 2 puffs OD Eklira Genuair (Aclidinium) 322mcg - 1 puff BD Seebri Breezhaler (Glycopyrronium) 44mcg 1 puff OD Combination Long-acting muscarinic antagonists & Long-acting beta 2 -agonists (LAMA+LABA) Anoro Ellipta (Umeclidinium / vilanterol) 55/22mcg - 1 puff OD Duaklir Genuair (Aclidinium / formoterol) 340/12mcg - 1 puff BD Spiolto Respimat (Tiotropium / olodaterol) 2.5/2.5mcg - 2 puffs OD Ultibro Breezhaler (Glycopyrronium / indacterol) 54/110mcg - 1 puff OD Combination Long-acting beta 2 -agonists & Inhaled corticosteroids (LABA+ICS) Relvar Ellipta (Fluticasone furoate / vilanterol) 92/22mcg - 1 puff OD Fostair MDI (Beclometasone / formoterol) 100/6mcg - 2 puffs BD Fostair Nexthaler (Beclometasone / formoterol) 100/6mcg - 2 puffs BD Symbicort Turbohaler (Budesonide / formoterol) 400/12mcg - 1 puff BD Seretide Accuhaler (Fluticasone / salmeterol) 500 mcg - 1 puff BD Combination Long-acting beta 2 -agonists, Long-acting muscarinic antagonists & Inhaled corticosteroids (LABA, LAMA+ICS) Trelegy Ellipta (Fluticasone furoate / umeclidinium / vilanterol) 92/55/22mcg - 1 puff OD See Coastal West Sussex Formulary ( for full list of approved drugs. (Green = first line choice) Other Maintenance Treatments Theophylline Consider if patient remains symptomatic despite, or intolerant of, inhaled therapy. Prescribe by brand name. Care in prescribing in the elderly and smokers due to altered pharmacokinetics, comorbidities and interactions. Reduce dose if macrolide or fluroquinolone antibiotics are prescribed. Mucolytic Consider a trial of carbocisteine 750mg TDS for 1-2 weeks in patients with productive cough. Continue only if symptoms improve at 1.5g daily in divided doses. Do not routinely prescribe to reduce exacerbations. Oral Corticosteroids Maintenance use is not normally recommended. Patients with advanced COPD may require maintenance therapy if corticosteroids cannot be successfully withdrawn following exacerbation. Page 6 of 10
7 Osteoporosis prophylaxis Patients treated with long-term oral corticosteroid therapy (intended for longer than 3 months) or frequent short courses of prednisolone should be monitored for the development of osteoporosis and given appropriate prophylaxis. Patients over the age of 65 should be started on prophylactic treatment, without monitoring. Refer to local osteoporosis guidelines. Nebulisers In most cases bronchodilator therapy is best administered using a hand-held inhaler device (including a spacer device if appropriate). Patients with distressing or disabling breathlessness despite maximal therapy should be considered for nebuliser therapy. Secondary care assessment is advised before consideration of nebulised therapy. Vaccination Pneumococcal vaccination and annual influenza vaccination should be offered to all COPD patients. Smoking Cessation All patients who smoke should be encouraged to stop and offered help to do so at every opportunity. Stopping smoking at any age reduces the rate of FEV 1 decline in patients with COPD. Pharmacotherapy and nicotine replacement reliably increase long-term smoking abstinence rates. To access smoking cessation services within Coastal West Sussex go to Long term Oxygen Therapy (LTOT) Assess the need for LTOT in patients with: very severe airflow obstruction, cyanosis, polycythaemia, peripheral oedema, raised JVP, oxygen saturations less than or equal to 92% on air. Consider referral of patients with severe airflow obstruction. LTOT should be used for a minimum of 15 hours per day. Smokers should be warned of the risk of fire. MANAGING EXACERBATIONS An exacerbation of COPD is defined as an acute worsening of respiratory symptoms that result in additional therapy. Exacerbations of COPD can be precipitated by several factors. The most common causes are respiratory tract infections. Treatment Short-acting inhaled beta2-agonists with or without short-acting anticholinergics, are recommended as the initial bronchodilators to treat an acute exacerbation. Oral corticosteroids i.e. prednisolone 30mg OD, can improve lung function, oxygenation and shorten recovery time. Duration of therapy should not be more than 5-7 days. Page 7 of 10
8 Antibiotics, when indicated, can shorten recovery time and reduce the risk of early relapse and treatment failure. Duration of therapy should be 5-7 days. See Microguide for formulary choice. PULMONARY REHABILITATION Pulmonary rehabilitation significantly increases exercise capacity, reduces dyspnoea and improves health related quality of life in COPD. Consider referral in all motivated patients post admission for exacerbation of COPD plus outpatients on optimum drug therapy with activities of daily living limited by breathlessness (normally mmrc grade 2 or higher) or decreasing exercise tolerance. SUPPORTIVE, PALLIATIVE, END-OF-LIFE & HOSPICE CARE Opioids should be used when appropriate for the palliation of breathlessness in endstage COPD unresponsive to other medical therapy. Consider the use of benzodiazepines, tricyclic antidepressants and oxygen. Refer to palliative care teams via the End of Life Hub (ECHO) option 3. Consider dietetic advice if the BMI is high or low. If BMI is below 20 give nutritional supplements and encourage exercise to augment the effects of supplementation. Pay attention to weight changes in older patients (especially >3kg). COPD COMMUNITY RESPIRATORY SERVICE COPD Community Respiratory Service Adur, Arun and Worthing localities Chanctonbury locality Chichester and Regis localities Oxygen review service Referral via OneCall - Telephone: Fax: Referral via OneCall - Telephone: Fax: No service available Pulmonary rehabilitation Referral via OneCall - Telephone: Fax: No service available Referral via OneCall - Telephone: Fax: British Lung Foundation Breathe Easy Support Groups Patient Education and peer support. Direct patients to Page 8 of 10
9 Appendix 1 COPD Assessment Test (CAT) Page 9 of 10
10 Appendix 2 Management of COPD in Adults Quick Reference Guide Page 10 of 10
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES Document Description Document Type Service Application Version Guidelines All healthcare professionals(hcps) caring for patients with asthma
More informationWirral COPD Prescribing Guidelines
Wirral COPD Prescribing Guidelines (To be read in conjunction with the Wirral COPD Supplementary Information) STEP 1: Assess symptoms COPD Assessment Test (CAT) [Link for CAT-test Online] is a patient-completed
More informationAlgorithm for the use of inhaled therapies in COPD
Berkshire West Integrated Care System Representing Berkshire West Clinical Commisioning Group Royal Berkshire NHS Foundation Trust Berkshire Healthcare NHS Foundation Trust Berkshire West Primary Care
More informationAlgorithm for the use of inhaled therapies in COPD Version 2 May 2017
Algorithm for the use of inhaled therapies in COPD This document has been revised by the Berkshire West Respiratory Network to support clinicians in selecting the most appropriate, cost effective treatments
More informationMedicines Management of Chronic Obstructive Pulmonary Disease (COPD)
Medicines Management of Chronic Obstructive Pulmonary Disease (COPD) (Chronic & Acute) Guidelines for Primary Care Guideline Authors: Shaneez Dhanji (Wandsworth CCG) Samantha Prigmore (St George s Hospital)
More informationCHARM Guidelines for the diagnosis and
\ CHARM Guidelines for the diagnosis and management of COPD City and Hackney CCG Homerton University Hospital NHS Foundation Trust Written by: Miss Hetal Dhruve, Specialist Pharmacist Respiratory Medicine,
More informationAddress Comorbidities
Greater Manchester COPD Management Plan Non-pharmacological management for ALL patients Smoking Cessation Annual Flu Vaccination Pulmonary Rehabilitation Increase daily activity Inhaler Technique Measure
More informationChronic Obstructive Pulmonary Disease (COPD) Treatment Guidelines
Chronic Obstructive Pulmonary Disease (COPD) Treatment Guidelines Where appropriate the following should be offered before commencing inhaled treatment: Offer treatment and support to stop smoking. Smoking
More informationPrescribing guidelines: Management of COPD in Primary Care
Prescribing guidelines: Management of COPD in Primary Care Establish diagnosis of COPD in patients 35 years with appropriate symptoms with history, examination and spirometry (FEV1/FVC ratio < 70%) Establish
More informationSABA: VENTOLIN EVOHALER (SALBUTAMOL) SAMA: ATROVENT IPRATROPIUM. Offer LAMA (discontinue SAMA) OR LABA
COPD GUIDELINES DIAGNOSIS >35 years of age Symptoms of cough, breathlessness, sputum, wheeze, Risk factor (SMOKING) Spirometry (post bronchodilator) FEV1/FVC = 0.7 ENCOURAGE PATIENTS TO BRING INHALERS
More informationCOPD Prescribing Guidelines
Cannock Chase Clinical Commissioning Group South East Staffordshire and Seisdon Peninsula Clinical Commissioning Group Stafford and Surrounds Clinical Commissioning Group East Staffordshire Clinical Commissioning
More informationCo. Durham & Darlington Respiratory Network COPD Treatment Guide
Co. Durham & Darlington Respiratory Network COPD Treatment Guide Age > 35, Productive cough, Breathless, Smoking Hx Spirometry (post-bronchodilator) COPD Advice Intensive smoking cessation support Vaccination
More informationNHS Dumfries & Galloway Triple therapy in COPD patients over 16 years
Title of Project: NHS Dumfries & Galloway Triple therapy in COPD patients over 16 years 1 Reason for the review Respiratory prescribing is long term and can be costly. Appropriate choice and use of inhaled
More informationTHE COPD PRESCRIBING TOOL
THE COPD PRESCRIBING TOOL Revised edition, 2017 www.bpac.org.nz/copd CLASSIFICATION The COPD prescribing tool This tool provides pharmacological treatment options for patients with COPD based on their
More informationGlobal Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health
Global Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions
More informationUp in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management. Colleen Sakon, PharmD BCPS September 27, 2018
Up in FLAMES: Stable Chronic Obstructive Pulmonary Disease (COPD) Management Colleen Sakon, PharmD BCPS September 27, 2018 Disclosures I have no actual or potential conflicts of interest 2 Objectives Summarize
More information2/4/2019. GOLD Objectives. GOLD 2019 Report: Chapters
GOLD Objectives To provide a non biased review of the current evidence for the assessment, diagnosis and treatment of patients with COPD. To highlight short term and long term treatment objectives organized
More informationRespiratory Inhalers. Identification Guide Version 3
Respiratory Inhalers Identification Guide Version 3 This booklet has been prepared by NHSGGC Medicines Information. Endorsed by NHSGGC Respiratory Managed Clinical Network, February 2017. Designed by Medical
More informationJOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES
JOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES Authors Dr Ian Benton Respiratory Consultant COCH Penny Rideal Respiratory Nurse COCH Kirti Burgul Respiratory Pharmacist COCH Pam
More informationChronic obstructive pulmonary disease
0 Chronic obstructive pulmonary disease Implementing NICE guidance June 2010 NICE clinical guideline 101 What this presentation covers Background Scope Key priorities for implementation Discussion Find
More informationDisclosure and Conflict of Interest 8/15/2017. Pharmacist Objectives. At the conclusion of this program, the pharmacist will be able to:
Digging for GOLD Rebecca Young, PharmD, BCACP, Roosevelt University College of Pharmacy Assistant Professor of Clinical Sciences Practice Site Advocate Medical Group-Nesset Pavilion Disclosure and Conflict
More information2017 GOLD Report. Is it worth its weight in GOLD??? CSHP-NB Fall Education Day September 30, 2017
2017 GOLD Report Is it worth its weight in GOLD??? CSHP-NB Fall Education Day September 30, 2017 Lauren Munro; BSc(Pharm) Amanda Burns; BSc(Pharm) Pharmacy Residents The Moncton Hospital Objectives Explain
More informationGuide to Inhaled Treatment Choices
Guide to Inhaled Treatment Choices Note: this is guidance only, it is important to consider which device is best suited to the patient. This may NOT be the first line choice (but should be on the joint
More informationGuide to Inhaled Treatment Choices
Guide to Inhaled Treatment Choices Note: this is guidance only, it is important to consider which device is best suited to the patient. This may NOT be the first line choice (but should be on the joint
More informationChanging Landscapes in COPD New Zealand Respiratory Conference
Changing Landscapes in COPD New Zealand Respiratory Conference Dr Robert Young BMedSc MBChB DPhil (Oxon) FRACP FRCP Associate Professor Consultant Physician Changing Landscapes in COPD: Summary 1. Overview
More informationCOPD GOLD Guidelines & Barnet inhaler choices. Dr Dean Creer, Respiratory Consultant, Royal Free London NHS Foundation Trust
COPD GOLD Guidelines & Barnet inhaler choices Dr Dean Creer, Respiratory Consultant, Royal Free London NHS Foundation Trust GOLD 2017 Report: Chapters 1. Definition and Overview 2. Diagnosis and Initial
More informationChronic Obstructive Pulmonary Disease (COPD) Management
DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC) Chronic Obstructive Pulmonary Disease (COPD) Management Diagnosis of COPD should be considered in patients over the age of 35 who have a risk factor (generally
More informationChronic Obstructive Pulmonary Disease (COPD) Primary Care Guideline
Chronic Obstructive Pulmonary Disease (COPD) Primary Care Guideline For use across all Norfolk & Waveney CCGs Based on GOLD 2017 1, NICE CG101 COPD 2. Norfolk & Waveney Group In the UK in 2012, 29,776
More informationChoosing an inhaler for COPD made simple. Dr Simon Hart Castle Hill Hospital
Choosing an inhaler for COPD made simple Dr Simon Hart Castle Hill Hospital 1 Declaration of interests I have received speaker fees, sponsorship to attend conferences, and funding for research from companies
More informationCOPD Update. Plus New and Improved Products for Inhaled Therapy. Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor
COPD Update Plus New and Improved Products for Inhaled Therapy Catherine Bourg Rebitch, PharmD, BCACP Clinical Associate Professor Disclosure The presenter has nothing to disclose concerning possible financial
More informationVA/DoD Clinical Practice Guideline Management of COPD Pocket Guide
VA/DoD Clinical Practice Guideline Management of COPD Pocket Guide MODULE A: MAAGEMET OF COPD 1 2 Patient with suspected or confirmed COPD presents to primary care [ A ] See sidebar A Perform brief clinical
More informationCOPD RESOURCE PACK Section 5. Drug Treatment & Inhalers in Stable COPD
COPD RESOURCE PACK Section 5 Drug Treatment & Inhalers in Stable COPD In this section: 1. Links to Fife Formulary 2. Pharmacological Management of Stable COPD 3. How to use a Metered Dose Inhaler 4. How
More informationCHRONIC OBSTRUCTIVE PULMONARY DISEASE
CHRONIC OBSTRUCTIVE PULMONARY DISEASE INCIDENCE UP TO 380,000 PEOPLE IN IRELAND HSE FIGURES 110,000 DIAGNOSED AND 200,000 UNDIAGNOSED. AFFECTS MORE MEN THAN WOMEN BUT RATES ARE RISING 1500 DEATHS PER YEAR
More informationCOPD Inhaled Therapy Prescribing Guidance
COPD Inhaled Therapy Prescribing Guidance For Basingstoke, Southampton and Winchester District Prescribing Committee This guidance applies to patients with a COPD DIAGNOSIS CONFIRMED BY POSTBRONCHODILATOR
More informationMedicines Management Programme Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD)
Medicines Management Programme Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD) Approved by Prof. Michael Barry, Clinical Lead, MMP. Date approved Version 1 July 2014 Date updated Version
More informationGuideline for the Diagnosis and Management of COPD
Guideline for the Diagnosis and Management of COPD Introduction Chronic obstructive pulmonary disease (COPD) is a respiratory disorder largely caused by smoking. It is characterized by progressive, partially
More informationPharmacotherapy for COPD
10/3/2017 Topics to be covered Pharmacotherapy for chronic treatment Pharmacotherapy for COPD Dr. W C Yu 3rd September 2017 Commonly used drugs Guidelines for their use Inhaled corticosteroids (ICS) in
More informationChronic Obstructive Pulmonary Disease (COPD) Guideline
Chronic Obstructive Pulmonary Disease (COPD) Guideline Unique ID: NHSL Author (s): Professor William MacNee, Dr. Gourab Choudhury. Lothian Respiratory (COPD) MCN Category/Level/Type: Level 2 Guideline
More informationEvidence Review for Prescribing Clinical Network
Summary page Evidence Review for Prescribing Clinical Network Treatment: LABA/LAMA Combination devices in COPD Anoro Ellipta, Ultibro and Duaklir Genuair Prepared by: Noreen Devanney Topic Submitted by:
More informationINHALERS for COPD INTRODUCTION. Types of inhalers. Inhaler technique. MDIs for COPD WET AEROSOLS. Dr Christopher Worsnop
INHALERS for COPD Dr Christopher Worsnop Department of Respiratory Medicine Austin Hospital INTRODUCTION Most drugs for COPD are given via inhalers. This reduces the dose that needs to be given and delivers
More informationDefining COPD. Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist
Defining COPD Georgina Grantham Community Respiratory Team Leader/ Respiratory Nurse Specialist Defining COPD Chronic Obstructive Pulmonary Disease (COPD) is a common, preventable and treatable disease
More informationCARE OF THE ADULT COPD PATIENT
CARE OF THE ADULT COPD PATIENT Target Audience: The target audience for this clinical guideline is all MultiCare providers and staff including those associated with our Clinically Integrated Network. The
More informationCOPD Inhaled Therapy Prescribing Guidance
COPD Inhaled Therapy Prescribing Guidance For Basingstoke, Southampton and Winchester District Prescribing Committee This guidance applies to patients with a COPD DIAGNOSIS CONFIRMED BY POSTBRONCHODILATOR
More informationCOPD Medications Coverage Summary Non-Insured Health Benefits Coverage SABA Bricanyl turbuhaler Yes Yes
COPD Medications Coverage Summary Drug Non-Insured Health Benefits Coverage SABA Bricanyl turbuhaler Yes Yes Ventolin MDI + generics Yes Yes Ventolin Diskus NO NO Yukon Pharmacare/Chronic Disease Program
More informationASTHMA PRESCRIBING GUIDELINES FOR ADULTS AND CHILDREN OVER 12
North Hampshire CCG Asthma Prescribing Guidelines June 2015 ASTHMA PRESCRIBING GUIDELINES FOR ADULTS AND CHILDREN OVER 12 These guidelines are based on the British Thoracic Society (BTS) and Scottish Intercollegiate
More informationSummary of Lothian Joint Formulary Amendments
Summary of Lothian Joint Formulary Amendments The purpose of this summary is to detail the main changes to the LJF sections and provide additional information on the reasons for some of the changes. The
More informationChronic Obstructive Pulmonary Disease (COPD)
NHS Eastern Cheshire Clinical Commissioning Group NHS South Cheshire Clinical Commissioning Group NHS Vale Royal Clinical Commissioning Group Mid Cheshire Hospitals NHS Foundation Trust East Cheshire NHS
More informationGlobal Strategy for the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline. MedStar Health
Global Strategy f the Diagnosis, Management and Prevention of COPD 2016 Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions
More informationDose. Route. Units. Given. Dose. Route. Units. Given
Chapter 4 Respiratory Andrew Stanton SALBUTAMOL (in acute asthma) 5 in acute asthma Nebulised (driven by oxygen not air) 4 6 hourly In acute severe asthma not responding to initial treatment or in life-threatening
More information3. Respiratory System
1 3. Respiratory System Also see Appendix 3A Guidance on Management of Also see Appendix 3B Preferred Inhaler Devices for Adults Also see Appendix 3C Preferred Inhaler Devices for Adolescents (12-18 years)
More informationTHEOPHYLLINE WITH INHALED CORTICOSTEROIDS (TWICS) TRIAL SELF MANAGMENT / ACTION PLANS GENUAIR INHALERS: POTENTIAL SAFETY ISSUE
I S S U E 4 M A R C H / A R P I L 2 0 1 6 Endorsed December 2014 I N S I D E T H I S I S S U E : Theophylline with Inhaled Corticosteroids (TWICS) Trial Genuair Inhaler: Potential Safety Issue 1 Self Management
More informationSurveillance report Published: 6 April 2016 nice.org.uk. NICE All rights reserved.
Surveillance report 2016 Chronic obstructive pulmonary disease in over 16s: diagnosis and management (2010) NICE guideline CG101 Surveillance report Published: 6 April 2016 nice.org.uk NICE 2016. All rights
More informationCOPD: Current Medical Therapy
COPD: Current Medical Therapy Angela Golden, DNP, FNP-C, FAANP Owner, NP from Home, LLC Outcomes As a result of this activity, learners will be able to: 1. List the appropriate classes of medications for
More informationGMMMG COPD Formulary Inhaler Options October 2017
BNF 3.1.1 Adrenocepter agonists (SABA) Salbutamol Salbutamol Terbutaline Brand name Airsalb Ventolin Evohaler Bricanyl Turbohaler Device MDI MDI Dry powder Strengths 100 microgram 100 microgram 500 microgram
More informationMedicines Management of Chronic Obstructive Pulmonary Disorder (COPD)
Medicines Management of Chronic Obstructive Pulmonary Disorder (COPD) Guidelines for Primary Care Guideline Authors: Shaneez Dhanji (NHS Wandsworth) and Reena Rabheru-Dodhy (NHS Sutton & Merton) Date Prepared:
More informationCOPD is a syndrome of chronic limitation in expiratory airflow encompassing emphysema or chronic bronchitis.
1 Definition of COPD: COPD is a syndrome of chronic limitation in expiratory airflow encompassing emphysema or chronic bronchitis. Airflow obstruction may be accompanied by airway hyper-responsiveness
More informationCOPD: Treatment Update Property of Presenter. Not for Reproduction. Barry Make, MD Professor of Medicine National Jewish Health
COPD: Treatment Update Barry Make, MD Professor of Medicine National Jewish Health Disclosures Advisory board, consultant, multi-center trial, research funding, Data Safety Monitoring Board (DSMB), or
More informationAdvances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015
Advances in the management of chronic obstructive lung diseases (COPD) David CL Lam Department of Medicine University of Hong Kong October, 2015 Chronic obstructive pulmonary disease (COPD) COPD in Hong
More informationOPTIMIZING MANAGEMENT OF COPD IN THE PRACTICE SETTING 10/16/2018 DISCLOSURES I have no financial or other disclosures
OPTIMIZING MANAGEMENT OF COPD IN THE PRACTICE SETTING J. Michael Fuller, MD, MEd, FACP, FCCP Associate Professor of Medicine University of South Carolina Greenville DISCLOSURES I have no financial or other
More informationSTRIVERDI RESPIMAT (olodaterol hcl) aerosol
STRIVERDI RESPIMAT (olodaterol hcl) aerosol Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationPosition within the Organisation
ASTHMA TREATMENT GUIDELINES Document Description Document Type Service Application Guidelines All healthcare professionals(hcps) caring for patients with asthma Version 4.0 Ratification date September
More informationGreater Manchester Asthma Management Plan 2018 Inhaler therapy options for adult patients (18 and over) with asthma
Greater Manchester Asthma Management Plan 2018 Inhaler therapy options for adult patients (18 and over) with asthma Non-pharmacological options for ALL patients, consider at ALL stages Make sure diagnosis
More informationCOPD: GOLD guidelines Ijlal Babar, MD Medical Director Pulmonary CCM, Pulmonary Hypertension Center SRHS
COPD: GOLD guidelines 2017 Ijlal Babar, MD Medical Director Pulmonary CCM, Pulmonary Hypertension Center SRHS Introduction The Global Initiative for Chronic Obstructive Lung Disease (GOLD) program was
More informationThree s Company - The role of triple therapy in chronic obstructive pulmonary
Three s Company - The role of triple therapy in chronic obstructive pulmonary disease (COPD) October 26 th, 2018 Zahava Picado, PharmD PGY1 Pharmacy Resident Central Texas Veterans Healthcare System Zahava.Picado@va.gov
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published. To view the latest
More informationCOPD: Preventable and Treatable. Lecture Outline. Diagnosis of COPD. COPD: Defining Terms
COPD: Preventable and Treatable Christopher H. Fanta, M.D. Partners Asthma Center Pulmonary and Critical Care Division Brigham and Women s Hospital Harvard Medical School Lecture Outline I. Diagnosis and
More informationCOPD Patient Care Pathway
COPD Patient Care Pathway Northumberland Clinical Commissioning Group North Tyneside Clinical Commissioning Group Contents The Pathway 1. Identification and Diagnosis.......................P3 2. Annual
More informationReport generated from BNF provided by FormularyComplete (www.pharmpress.com). Accessed Formulary Status. TA Number. Section.
Report generated from BNF provided by FormularyComplete (www.pharmpress.com). Accessed 16 02 2017 Title Formulary Status Section TA Number TA Link Annotation ACLIDINIUM BROMIDE bronchodilators ADRENALINE/EPINEPHRINE
More informationaclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A.
aclidinium 322 micrograms inhalation powder (Eklira Genuair ) SMC No. (810/12) Almirall S.A. 05 October 2012 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and
More informationglycopyrronium 44 micrograms hard capsules of inhalation powder (Seebri Breezhaler ) SMC No. (829/12) Novartis Pharmaceuticals Ltd.
glycopyrronium 44 micrograms hard capsules of inhalation powder (Seebri Breezhaler ) SMC No. (829/12) Novartis Pharmaceuticals Ltd. 07 December 2012 The Scottish Medicines Consortium (SMC) has completed
More informationMedical Directive. Activation Date: April 24, 2013 Review due by: December 1, Medical Director: Date: December 1, 2017
Medical Directive Pre and Post Bronchodilator Spirometry Testing and Treatment Initiation Assigned Number: Activation Date: April 24, 2013 Review due by: December 1, 2019 23 Approval Signature & Date Medical
More informationCOPD The New Epidemic. Peter Lin MD CCFP Director Primary Care Initiatives Canadian Heart Research Centre
COPD The New Epidemic Peter Lin MD CCFP Director Primary Care Initiatives Canadian Heart Research Centre Conflict Disclosure Information Speaker: Dr. Peter Lin Title of Talk: COPD The New Epidemic Financial
More informationTest Your Inhaler Knowledge
A Breath of Fresh Air: Updates in COPD Management Jennifer Austin Szwak, PharmD, BCPS, DPLA University of Chicago Medicine The speaker has nothing to disclose Abbreviations COPD: Chronic obstructive pulmonary
More informationCOPD/Asthma. Prudence Twigg, AGNP
COPD/Asthma Prudence Twigg, AGNP COPD/Asthma Qualifying Diagnosis Known diagnosis of COPD/asthma or CXR showing COPD with hyperinflated lungs and no infiltrates + two or more: Wheezing, SOB, increased
More informationChronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease (COPD) Definition of COPD Airflow obstruction that is: o Not fully reversible o Progressive o Does not change markedly over several months Combination of airway and
More informationBEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE
BEDFORDSHIRE AND LUTON JOINT PRESCRIBING COMMITTEE Bulletin 218: September 2015 Review Date: September 2018 LAMA / LABA combination inhalers in COPD- Place in therapy review and choice of therapy JPC Recommendations:
More informationChronic Obstructive Pulmonary Disease Guidelines and updates
Chronic Obstructive Pulmonary Disease Guidelines and updates October 20, 2018 Saratoga Springs, NY COPD (Chronic obstructive pulmonary disease) is a major cause of mortality and morbidity in the United
More informationOutline. EPIC Project. February EPIC Project. Diagnosis: Spirometry. Differentiation between COPD & Asthma
EPIC Project Enabling Patient health Improvements though COPD medicines optimisation Dr Toby Capstick Toby.capstick@nhs.net Outline Background on COPD COPD Assessment Cost Effective Treatment Medication
More informationRoflumilast (Daxas) for chronic obstructive pulmonary disease
Roflumilast (Daxas) for chronic obstructive pulmonary disease August 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationumeclidinium, 55 micrograms, powder for inhalation (Incruse ) SMC No. (1004/14) GlaxoSmithKline
umeclidinium, 55 micrograms, powder for inhalation (Incruse ) SMC No. (1004/14) GlaxoSmithKline 07 November 2014 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationCOPD-X. Concise Guide for Primary Care
www.copdx.org.au This Guide aims to provide evidence-based practical recommendations for healthcare professionals on the diagnosis and management of chronic obstructive pulmonary disease (COPD). COPD-X
More informationAsthma Treatment Guideline for Adults (aged 17 and over)
Asthma Treatment Guideline for Adults (aged 17 and over) Sharon Andrew MLCSU January 2019 (Review date 0 January 2022) VERSION CONTROL. Please access via the LMMG website to ensure that the correct version
More informationCOPD 2016 What to do with all these New Inhalers?
COPD 2016 What to do with all these New Inhalers? Planning committee Content Experts Clinical reviewers Paul Hernandez MDCM FRCPC, Department of Respirology, QEII Health Sciences Centre, Associate Professor,
More informationCOPD Robert Schilz DO, PhD Pulmonary, Critical Care and Sleep Medicine University Hospitals Case Medical Center
COPD 2018 GOLD 2017 Report Global Initiative for Chronic Obstructive Lung D isease COPYRIGHTED MATERIAL- DO NOT COPY OR DISTRIBUTE GLOBAL STRATEGY FOR THE DIAGNOSIS, MANAGEMENT, AND PREVENTION OF CHRONIC
More informationCOPD: A Renewed Focus. Disclosures
COPD: A Renewed Focus Heath Latham, MD Assistant Professor Division of Pulmonary and Critical Care Medicine Disclosures No Business Interests No Consulting No Speakers Bureau No Off Label Use to Discuss
More informationCurriculum Vitae. Head of Public Wing HCU - RSCM. Head of ICU Sari Asih Ciledug Hospital
Curriculum Vitae Name : Dr. Ceva W. Pitoyo,SpPD,K-P,KIC,FINASIM POB / DOB : Jakarta, March 8th 1968 Education : o General Practitioner : FKUI 1993 o Internist : FKUI 2002 o Pulmonology Consultant : PAPDI-UI
More informationChronic Obstructive Pulmonary Disease: What s New in Therapeutic Management?
Chronic Obstructive Pulmonary Disease: What s New in Therapeutic Management? Sabrina Sherwood, PharmD PGY2 Internal Medicine Resident University of Utah Health September 29, 2018 Disclosures Relevant disclosures
More informationThese lung function tests involve you being seated and breathing into specialist equipment (like that shown below), via a filter and a mouthpiece.
Lung Function Tests This leaflet only gives you general information about the lung function (breathing) tests. However, it does not replace the need for the personal advice from the health care professional.
More informationChapter 3: Respiratory System (7 th Edition)
Chapter 3: Respiratory System (7 th Edition) The Sheffield respiratory guidelines (April 2015) have been removed from the intranet. This is because the COPD section has been superseded by the COPD treatment
More informationCOPD in primary care: reminder and update
COPD in primary care: reminder and update Managing COPD continues to be a major feature of primary care, particularly in practices with a high proportion of M ori and Pacific peoples. COPDX clinical practice
More informationClinical Policy: Roflumilast (Daliresp) Reference Number: CP.PMN.46 Effective Date: Last Review Date: 08.18
Clinical Policy: (Daliresp) Reference Number: CP.PMN.46 Effective Date: 11.01.11 Last Review Date: 08.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationTHE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable
THE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable This activity is supported by an educational grant from Sunovion Pharmaceuticals Inc. COPD in the United States Third leading cause
More informationCommunity COPD Service Protocol
Community COPD Service Protocol Acknowledgements This protocol is based on the following documents: 1. Chronic obstructive pulmonary disease: Management of chronic obstructive pulmonary disease in adults
More informationInclude patients: with a confirmed diagnosis of asthma who have been free of asthma symptoms for 3 months or more.
Corby Clinical Commissioning Group Kettering General Hospital NHS Trust Nene Clinical Commissioning Group rthampton General Hospital NHS Trust rthamptonshire Healthcare Foundation Trust Stepping down asthma
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Chronic obstructive pulmonary disease: the management of adults with chronic obstructive pulmonary disease in primary and secondary
More informationChronic obstructive pulmonary disease
Chronic obstructive pulmonary disease Management of chronic obstructive pulmonary disease in adults in primary and secondary care (partial update) Issued: June 2010 NICE clinical guideline 101 guidance.nice.org.uk/cg101
More informationTRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder
TRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
More informationApril 10 th, Bond Street, Toronto ON, M5B 1W8
Comprehensive Research Plan: Inhaled long-acting muscarinic antagonists (LAMAs; long-acting anticholinergics) for the treatment of chronic obstructive pulmonary disease (COPD) April 10 th, 2014 30 Bond
More informationChronic obstructive pulmonary disease
Chronic obstructive pulmonary disease Abstract Whittaker C, BPharm, MRPharmS Amayeza Info Centre Chronic obstructive pulmonary disease affects millions of people, has a major impact on quality of life
More information